SUMMARY Angioimmunoblastic lymphadenopathy (AILD) is a lymphoproliferative disorder with well established clinical and histological features,1-3 one of the clinical manifestations being a peripheral polyarthritis.4 A case of AILD with a symmetrical non-erosive peripheral polyarthritis is described, including the findings in the synovial fluid and histology of the synovium. There was a marked reduction in the number of peripheral blood T lymphocytes bearing the CDT8 phenotype in both the peripheral blood and synovial fluid. The arthritis was difficult to control, requiring large doses of corticosteroids, which produced significant side effects. Levamisole 150 mg, one day each week, was effective in controlling the arthritis and returning the numbers of CDT8 lymphocytes to normal. The aetiology of AILD is unknown, though a defect in T cell regulation, in particular T cell suppression, with a secondary B cell proliferation has been postulated.1 2 The demonstration of reduced numbers of lymphocytes bearing the CDT8 phenotype in this patient supports that theory.
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Angioimmunoblastic lymphadenopathy (AILD) is a lymphoproliferative disorder with well described characteristic clinical and histological features.1-It has a clinical similarity to several connective tissue disorders, including Sj6gren's syndrome and systemic lupus erythematosus (SLE), with which it has been associated.5 Infrequently there may be an associated arthritis,4 69 which is usually seronegative, only three cases having been reported as being seropositive for 1gM rheumatoid factor.6 7 In the few cases in which the arthritis has been fully described it was symmetrical, peripheral, and non-erosive.
The aetiology of AILD is unknown, though a defect in T cell regulation, probably T cell suppression with secondary B cell proliferation, has been postulated. ' (Fig. 2) .
More aggressive chemotherapy using cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP regimen) was used with regression of the lymphadenopathy but with a return of the synovitis when the prednisone was reduced below 30 mg/day. This regimen produced a hypogammaglobulinaemia, IgG 3-6 g/l, IgA 0-06 g/l, and IgM 0-3 g/l, which has persisted. Over the next few months the patient's illness was complicated by recurrent breast abscesses, right upper lobe pneumonia, proximal myopathy, and osteoporosis with vertebral fractures. It was thought that these complications were corticosteroid induced. In May 1984 she was given gold salts to try and control the arthritis so that the prednisone dosage could be reduced. This had to be discontinued after four months (total dose 800 mg) because of gold induced neutropenia. A bone marrow showed abnormal development of myeloid (Table 1) .
The patient remained on levamisole, 50-150 mg/day, for one day a week to control her arthritis. There were some fluctuations in her white cell count and lymphocyte subsets, the last relatively normal result being in February 1986 (Table 2 ). Over subsequent months there was a recurrence of the lymphadenopathy with a progressive pancytopenia, and in June the patient died from septicaemia. Levamisole was discontinued at the time of the recurrence of the lymphadenopathy, without any recurrence of the arthritis.
Discussion
The clinical features of AILD, fever, weight loss, lymphadenopathy, hepatomegaly, skin rash, hypergammaglobulinaemia, and polyarthritis, were all present in this patient. In addition, there was fine miliary calcification in the lungs consistent with chicken pox lung. This patient had a marked reduction in the numbers of CDT8 cells in the peripheral blood and synovial fluid with a hypergammaglobulinaemia. The total lymphocyte count was at the lower limit of the normal range. This would be consistent with the hypothesis of an impairment of T cell suppression. Other studies have mentioned a reduction in peripheral blood total T cell numbers but not commented on a selective reduction in CDT8 cells. 4 Synovial fluid was obtained in two previous cases, one contained a moderate number of leucocytes with 88% neutrophils6 and the other 15 300 leucocytes, of which 70% were neutrophils and 29% large mononuclear leucocytes and 1% small lymphocytes.7 Synovial biopsy in a third case with bilateral carpal tunnel syndrome and polyarthropathy showed a mononuclear cell infiltrate, but no other features were mentioned. 4 The synovial histology in this case was non-specific, but the important feature was the lack of an inflammatory cell infiltrate.
AILD and SLE share many clinical manifestations as well as hypergammaglobulinaemia and lymphopenia. In addition, in vitro T suppressor cell defects have been reported in patients with SLE."
Although lymph node histology and autoantibody profiles differentiate the two conditions, it is possible that they could form a continuous spectrum of disease that may share a common pathogenic mechanism. One of these mechanisms may be a T suppressor cell defect which could also predispose towards development of an arthritis. Although initially thought to be benign, it is now known that AILD carries a 50% mortality at 12 months, reaching 90% if no remission is achieved with chemotherapy.4
In this patient an aggressive chemotherapeutic regimen was effective in controlling the disease but not the polyarthritis. The high dose of prednisone (>30 mg/day) required to control the polyarthritis resulted in severe side effects. Gold salts produced only a partial clinical improvement before they were discontinued because of neutropenia. The interesting observation was the beneficial effect of levamisole which occurred over a three months' period, the clinical improvement being associated with an improvement in the numbers of T suppressor cells.
This enabled the prednisone dosage to be significantly reduced to a maintenance dose of 3 mg/day.
Levamisole has been previously used in the treatment of AILD with or without an arthritis and may correct a lymphopenia. It has been assumed that it corrects the defect in T cell suppression,8 [12] [13] [14] the dosage of levamisole being 150 mg two or three days a week. We used a smaller dose of 150 mg one day a week, because it has been shown to be adequate in controlling rheumatoid arthritis. '5 Therefore this case shows how polyarthritis in AILD may be a major symptomatic manifestation of the condition which can b-difficult to control. Levamisole was effective in controlling the polyarthritis and correcting the lymphocyte subset abnormality, allowing a reduction in the corticosteroid dosage. Levamisole 
